Zacks Investment Research
08 Jul 2026, 22:51 UTC · 2h ago
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

Zacks Investment Research
08 Jul 2026, 22:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims
3 claims · each scored for market impact
Viking Therapeutics (VKTX) is expected to report earnings per share (EPS) of -$1.21, a decrease of 108.62% from the prior-year quarter. — A significant year-over-year drop in expected earnings typically pressures a stock's price ahead of an earnings release.
-0.60Viking Therapeutics currently holds a Zacks Rank of #4 (Sell). — A quantitative 'Sell' rating from a major research provider suggests a bearish short-term outlook.
-0.40VKTX shares closed the most recent trading day down 5.13%, underperforming the S&P 500. — Recent price momentum is negative and trailing the broader market, indicating waning investor sentiment.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The stock price dropped over 5% in the most recent session, it carries a Zacks Rank of #4 (Sell), and expected EPS is down significantly from the prior-year quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works

Zacks Investment Research
2h ago